Recent Highlights
- Achieved record revenue of
$16.8 million in the third quarter of 2016, an increase of 80% over the same period of the prior year - Completed initial public offering, receiving net proceeds of approximately
$111 million - Study results presented at the
American Heart Association (AHA) Scientific Sessions suggest that extended continuous cardiac monitoring using its Zio® Service is more useful for arrhythmia detection than Holter monitoring in patients with adult congenital heart disease (ACHD).
"I am encouraged by the strong adoption we are experiencing for our Zio Service. To date, we have provided our service to more than 500,000 patients and received broad U.S. payor coverage estimated to be over 290 million patients, said
Third Quarter Financial Results
Revenue for the three months ended
Gross profit for the third quarter of 2016 was
Operating expenses for the third quarter of 2016 were
Loss from operations for the third quarter of 2016 was
Cash, cash equivalents, and short-term investments were
Guidance for Full Year 2016
iRhythm projects revenue for full year 2016 to be in the range of
Webcast and Conference Call Information
iRhythm’s management team will host a conference call today beginning at
About
iRhythm is a commercial-stage digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients. The company’s platform, the Zio Service, has been provided to over 500,000 patients, accumulating more than 125 million hours of curated heartbeat data within iRhythm’s data repository.
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. These statements include statements regarding financial guidance. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our third quarter Form 10-Q filing made with the
[Financial Tables to Follow]
| IRHYTHM TECHNOLOGIES, INC. | ||||||||
| Condensed Consolidated Balance Sheets | ||||||||
| (Unaudited) | ||||||||
| (In thousands, except share and per share data) | ||||||||
| September 30, 2016 |
December 31, 2015 |
|||||||
| Assets | ||||||||
| Current assets: | ||||||||
| Cash and cash equivalents | $ | 5,761 | $ | 25,208 | ||||
| Accounts receivable, net | 9,308 | 5,577 | ||||||
| Inventory | 1,672 | 1,145 | ||||||
| Prepaid expenses and other current assets | 1,013 | 808 | ||||||
| Restricted cash | 91 | 91 | ||||||
| Total current assets | 17,845 | 32,829 | ||||||
| Property and equipment, net | 3,363 | 2,036 | ||||||
| Goodwill | 862 | 862 | ||||||
| Other assets | 5,310 | 2,145 | ||||||
| Total assets | $ | 27,380 | $ | 37,872 | ||||
| Liabilities, Convertible Preferred Stock and Stockholders’ Deficit | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | 1,581 | $ | 1,459 | ||||
| Accrued liabilities | 6,894 | 6,699 | ||||||
| Deferred revenue | 850 | 506 | ||||||
| Accrued interest, current portion | - | 111 | ||||||
| Total current liabilities | 9,325 | 8,775 | ||||||
| Debt | 31,796 | 30,552 | ||||||
| Deferred rent, noncurrent portion | 27 | 28 | ||||||
| Accrued interest, net of current portion | 119 | 96 | ||||||
| Preferred stock warrant liabilities | 3,945 | 2,949 | ||||||
| Total liabilities | 45,212 | 42,400 | ||||||
| Commitments and contingencies | ||||||||
| Convertible preferred stock, $0.001 par value – 11,392,882 and 11,392,882 shares authorized at September 30, 2016 and December 31, 2015, respectively; 11,046,146 and 11,046,146 shares issued and outstanding at September 30, 2016 and December 31, 2015, respectively; aggregate liquidation preference of $117,495, and $117,495 at September 30, 2016 and December 31, 2015, respectively |
97,096 | 97,096 | ||||||
| Stockholders’ deficit: | ||||||||
| Common stock, $0.001 par value – 18,528,913 and 18,528,913 shares authorized at September 30, 2016 and December 31, 2015, respectively; 1,455,020 and 1,410,565 shares issued and outstanding at and September 30, 2016 December 31, 2015, respectively |
1 | 1 | ||||||
| Additional paid-in capital | 5,974 | 4,641 | ||||||
| Accumulated deficit | (120,903 | ) | (106,266 | ) | ||||
| Total stockholders’ deficit | (114,928 | ) | (101,624 | ) | ||||
| Total liabilities, convertible preferred stock and stockholders’ deficit | $ | 27,380 | $ | 37,872 | ||||
| IRHYTHM TECHNOLOGIES, INC. | ||||||||||||||||
| Condensed Consolidated Statements of Operations and Comprehensive Loss | ||||||||||||||||
| (Unaudited) | ||||||||||||||||
| (In thousands, except share and per share data) | ||||||||||||||||
| Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
| 2016 | 2015 | 2016 | 2015 | |||||||||||||
| Revenue | $ | 16,780 | $ | 9,344 | $ | 45,368 | $ | 25,286 | ||||||||
| Cost of revenue | 5,282 | 3,748 | 15,097 | 10,539 | ||||||||||||
| Gross profit | 11,498 | 5,596 | 30,271 | 14,747 | ||||||||||||
| Operating expenses: | ||||||||||||||||
| Research and development | 1,635 | 1,651 | 4,847 | 4,549 | ||||||||||||
| Selling, general and administrative | 12,529 | 9,445 | 36,658 | 24,935 | ||||||||||||
| Total operating expenses | 14,164 | 11,096 | 41,505 | 29,484 | ||||||||||||
| Loss from operations | (2,666 | ) | (5,500 | ) | (11,234 | ) | (14,737 | ) | ||||||||
| Interest expense | (807 | ) | (222 | ) | (2,388 | ) | (477 | ) | ||||||||
| Other expense, net | (602 | ) | (24 | ) | (1,015 | ) | 117 | |||||||||
| Net loss and comprehensive loss | $ | (4,075 | ) | $ | (5,746 | ) | $ | (14,637 | ) | $ | (15,097 | ) | ||||
| Net loss per common share, basic and diluted | $ | (2.80 | ) | $ | (4.07 | ) | $ | (10.20 | ) | $ | (11.07 | ) | ||||
| Weighted-average shares used to compute net loss per common share, basic and diluted |
1,454,307 | 1,409,758 | 1,434,583 | 1,364,366 | ||||||||||||
Investor Relations Contact:Lynn Pieper Lewis orLeigh Salvo (415) 937-5404 investors@irhythmtech.com Media ContactAaron Murphy (415) 229-3331 media@irhythmtech.com